Complement-mediated neutralization of dengue virus requires mannose-binding lectin

mBio

Volumn 2, Issue 6, 2011, Pages

  Avirutnan, Panisadee ^a,b   Hauhart, Richard E ^a   Marovich, Mary A ^c   Garred, Peter ^d   Atkinson, John P ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; GENETIC VARIABILITY; HUMAN; INFECTION CONTROL; INSECT CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SEROTYPE; VIRUS NEUTRALIZATION;

DENGUE VIRUS; FLAVIVIRUS; HEXAPODA; MAMMALIA; MUS; WEST NILE VIRUS;

EID: 84855243173     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00276-11     Document Type: Article

References (57)

1. Thomas SJ, Endy TP. 2011. Critical issues in dengue vaccine development. Curr. Opin. Infect. Dis. 24:442-450.
2. Nimmannitya S. 1987. Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J. Trop. Med. Public Health 18: 392-397.
3. Martina BE, Koraka P, Osterhaus AD. 2009. Dengue virus pathogenesis: an integrated view. Clin. Microbiol. Rev. 22:564-581.
4. Heinz FX, Allison SL. 2003. Flavivirus structure and membrane fusion. Adv. Virus Res. 59:63-97.
5. Pokidysheva E, et al. 2006. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124:485-493.
6. Tassaneetrithep B, et al. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197:823-829.
7. van der Schaar HM, et al. 2008. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog. 4:e1000244.
8. Mackenzie JM, Westaway EG. 2001. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticu-lum and along the secretory pathway, respectively. J. Virol. 75: 10787-10799.
9. Kuhn RJ, et al. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
10. Sørensen R, Thiel S, Jensenius JC. 2005. Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin. Immunopathol. 27:299-319.
11. Dumestre-Pérard C, et al. 2008. Aspergillus conidia activate the complement by the mannan-binding lectin C2 bypass mechanism. J. Immunol. 181:7100-7105.
12. Matsushita M, Fujita T. 1995. Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation. Immunobiology 194: 443-448.
13. Selander B, et al. 2006. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J. Clin. Invest. 116:1425-1434.
14. Ip WK, Takahashi K, Ezekowitz RA, Stuart LM. 2009. Mannose-binding lectin and innate immunity. Immunol. Rev. 230:9-21.
15. Garred P, Larsen F, Madsen HO, Koch C. 2003. Mannose-binding lectin deficiency-revisited. Mol. Immunol. 40:73-84.
16. Degn SE, Jensenius JC, Thiel S. 2011. Disease-causing mutations in genes of the complement system. Am. J. Hum. Genet. 88:689-705.
17. Eisen DP, Minchinton RM. 2003. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis. 37:1496-1505.
18. Chong WP, et al. 2005. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 42:1037-1045.
19. Koutsounaki E, et al. 2008. Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients. J. Clin. Immunol. 28:495-500.
20. Seppänen M, et al. 2009. Mannose-binding lectin 2 gene polymorphism in recurrent herpes simplex virus 2 infection. Hum. Immunol. 70: 218-221.
21. Tan Y, et al. 2009. Association between mannose-binding lectin and HIV infection and progression in a Chinese population. Mol. Immunol. 47: 632-638.
22. Avirutnan P, et al. 2006. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193:1078-1088.
23. Bokisch VA, Top FH, Jr, Russell PK, Dixon FJ, Müller-Eberhard HJ. 1973. The potential pathogenic role of complement in dengue hemor-rhagic shock syndrome. N. Engl. J. Med. 289:996-1000.
24. Malasit P. 1987. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J. Trop. Med. Public Health 18:316-320.
25. Fuchs A, et al. 2010. Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 8:186-195.
26. Hacker K, White L, de Silva AM. 2009. N-linked glycans on dengue viruses growninmammalian and insect cells. J. Gen. Virol. 90:2097-2106.
27. Vorup-Jensen T, et al. 2001. Recombinant expression of human mannan-binding lectin. Int. Immunopharmacol. 1:677-687.
28. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7:e1002111.
29. Lok SM, et al. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-317.
30. Zhang MX, Kozel TR. 1998. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albi-cans via the alternative complement pathway. Infect. Immun. 66: 4845-4850.
31. Zhang MX, Lupan DM, Kozel TR. 1997. Mannan-specific immunoglob-ulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect. Immun. 65:3822-3827.
32. Blanchong CA, et al. 2001. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int. Immunopharmacol. 1:365-392.
33. Gubler DJ, Kuno G, Markoff L. 2007. Flaviviruses, p 1153-1252. In Knipe DM and Howley PM (ed), Fields virology, 5th ed, vol 1. Lippincott Williams and Wilkins, Philadelphia, PA.
34. Fuchs A, Pinto AK, Schwaeble WJ, Diamond MS. 2011. The lectin pathway of complement activation contributes to protection from West Nile virus infection. Virology 412:101-109.
35. Anders EM, Hartley CA, Reading PC, Ezekowitz RA. 1994. Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin. J. Gen. Virol. 75(Part 3):615-622.
36. Brown KS, et al. 2010. Specific interaction of hepatitis C virus glycopro-teins with mannan binding lectin inhibits virus entry. Protein Cell 1:664-674.
37. Gadjeva M, et al. 2004. Mannan-binding lectin modulates the response to HSV-2 infection. Clin. Exp. Immunol. 138:304-311.
38. Haurum JS, et al. 1993. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 7:1307-1313.
39. Ip WK, et al. 2005. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J. Infect. Dis. 191:1697-1704.
40. Ji X, et al. 2005. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J. Gen. Virol. 86:2535-2542.
41. Wakimoto H, et al. 2002. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5:275-282.
42. Ezekowitz RA, Kuhlman M, Groopman JE, Byrn RA. 1989. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J. Exp. Med. 169:185-196.
43. Kase T, et al. 1999. Human mannan-binding lectin inhibits the infection of influenza A virus without complement. Immunology 97:385-392.
44. Stoermer KA, Morrison TE. 2011. Complement and viral pathogenesis. Virology 411:362-373.
45. Acioli-Santos B, et al. 2008. MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue pheno-type. Hum. Immunol. 69:122-128.
46. Loke H, et al. 2002. Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation inthe vitaminDrecep-tor and Fc gamma receptor IIa genes. Am. J. Trop. Med. Hyg. 67:102-106.
47. Balmaseda A, et al. 2010. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J. Infect. Dis. 201:5-14.
48. Burke DS, Nisalak A, Johnson DE, Scott RM. 1988. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38:172-180.
49. Endy TP, et al. 2002. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am. J. Epidemiol. 156:40-51.
50. Gaunt MW, et al. 2001. Phylogenetic relationships of flaviviruses correlate with their epidemiology, disease association and biogeography. J.Gen. Virol. 82:1867-1876.
51. Thiel S. 2007. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol. Immunol. 44:3875-3888.
52. Madsen HO, et al. 1995. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J. Immunol. 155:3013-3020.
53. Boonnak K, et al. 2008. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J. Virol. 82:3939-3951.
54. Oliphant T, et al. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 80:12149-12159.
55. Gentry MK, Henchal EA, McCown JM, Brandt WE, Dalrymple JM. 1982. Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am. J. Trop. Med. Hyg. 31:548-555.
56. Sabo MC, Luca VC, Prentoe J, et al. 2011. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 85: 7005-7019.
57. Giclas PC. 1994. Classical pathway evaluation, p 13.1.1-13.1.26. In Coli-gan JE, Kruisbeek AM, Margulies DH, Shevak EM, Strober W (ed), Current protocols in immunology, vol 3. John Wiley & Sons, Hoboken, NJ.